DuoBody-CD3xCD20 (GEN3013)

DuoBody®-CD3xCD20 (GEN3013) is a proprietary bispecific antibody created using Genmab’s DuoBody technology. It targets CD20, a clinical well-validated target. In a number of laboratory models, this DuoBody has shown unusually high potency in killing CD20+ tumors. DuoBody-CD3xCD20 has potential in multiple hematological malignancies.  A Phase I/II study in hematological malignancies including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma and marginal zone lymphoma started in 2018.

Back to top

DuoBody-CD3xCD20 has potential in multiple hematological malignancies. A Phase I/II study in hematological malignancies including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, follicular lymphoma,  mantle cell lymphoma, small lymphocytic lymphoma and marginal zone lymphoma is ongoing. For more information, visit clinicaltrials.gov.

Back to top